Macrogenics (MGNX) Enterprise Value (2012 - 2026)
Macrogenics (MGNX) posted quarterly Enterprise Value of -$66.5 million for Q1 2026, up 54.31% year-over-year from -$43.1 million in Q1 2025, and down 16.25% quarter-over-quarter from -$57.2 million in Q4 2025.
Macrogenics (MGNX) Enterprise Value (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Enterprise Value for 15 consecutive years, with -$66.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 54.31% year-over-year to -$66.5 million; the TTM figure through Mar 2026 stood at -$66.5 million (up 54.31% YoY), while the FY2025 annual figure was -$57.2 million, up 68.71% from the prior year.
- Enterprise Value fell to -$66.5 million in Q1 2026 per MGNX's latest filing, from -$57.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$21.5 million in Q2 2022 and bottomed at -$224.3 million in Q1 2023.
- Historically, Enterprise Value has averaged -$105.4 million across 5 years, with a median of -$89.9 million in 2023.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 88.64% — and 2023, when it plunged 406.58%.
- Macrogenics' Enterprise Value stood at -$108.9 million in 2022, then increased by 7.28% to -$101.0 million in 2023, then plunged by 81.11% to -$182.8 million in 2024, then soared by 68.71% to -$57.2 million in 2025, then declined by 16.25% to -$66.5 million in 2026.
- Business Quant data shows MGNX's Enterprise Value at -$66.5 million in Q1 2026, -$57.2 million in Q4 2025, and -$80.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -66.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.52 Mn |
| Dec 31, 2025 | -57.22 Mn |
| Sep 30, 2025 | -80.13 Mn |
| Jun 30, 2025 | -130.69 Mn |
| Mar 31, 2025 | -145.57 Mn |
| Dec 31, 2024 | -182.84 Mn |
| Sep 30, 2024 | -179.63 Mn |
| Jun 30, 2024 | -83.93 Mn |
| Mar 31, 2024 | -80.36 Mn |
| Dec 31, 2023 | -100.96 Mn |
| Sep 30, 2023 | -89.90 Mn |
| Jun 30, 2023 | -108.76 Mn |
| Mar 31, 2023 | -224.26 Mn |
| Dec 31, 2022 | -108.88 Mn |
| Sep 30, 2022 | -83.99 Mn |
| Jun 30, 2022 | -21.47 Mn |
| Mar 31, 2022 | -47.33 Mn |
| Dec 31, 2021 | -123.47 Mn |
| Sep 30, 2021 | -190.53 Mn |
| Jun 30, 2021 | -188.97 Mn |